AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

DIMERIX LTD

0.230

0.000

Volume:271.61K

Turnover:62.83K

Market Cap:138.09M

PE:-4.63

High:0.235

Open:0.235

Low:0.225

Close:0.230

52wk High:0.665

52wk Low:0.157

Shares:600.40M

Float Shares:467.70M

Volume Ratio:0.32

T/O Rate:0.06%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.050

EPS(LYR):-0.050

ROE:-594.54%

ROA:-29.36%

PB:-9.36

PE(LYR):-4.63

Loading ...

Overview Company News Filings

Dimerix Receives AU$17 Million in Proceeds After Completing Initial Drawdown Under Non-Dilutive Funding Facility

MT Newswires Live

Dimerix Ltd-Waiver of Listing Rule 10.1 Granted

THOMSON REUTERS

Dimerix - Waiver Permits Security Grant to Skiptan Entities Without Shareholder Approval

THOMSON REUTERS

Australia's Dimerix Rises on Patent Approval in Mexico

Dimerix Says Mexican Composition of Matter Patent Granted for Drug Candidate

MT Newswires Live

Dimerix Ltd-Dimerix Dmx-652 Granted Mexican Composition of Matter Patent

THOMSON REUTERS

Dimerix Secures AU$34 Million in Non-Dilutive Loan Facility Agreements; Shares Up 4%

MT Newswires Live

Dimerix Ltd - Secures A$34 Mln Non-Dilutive Funding Facility

THOMSON REUTERS

Dimerix - Trading Halt Requested Pending Announcement on Non-Dilutive Funding Arrangements

THOMSON REUTERS

Dimerix Posts Loss for Year Attributable of A$29.8 Million

Dimerix Ltd - Loss for the Year Attributable A$29.8 Mln

THOMSON REUTERS

Dimerix Receives Initial $10 Million Upfront Payment Under Everest Medicines License Deal; Shares Gain 4%

MT Newswires Live

Dimerix Completes Transfer of Acute Kidney Injury Drug Candidate's US Investigational New Drug Application, Shares Up 6%

MT Newswires Live

Dimerix Ltd-Dimerix Assumes Sponsorship of US Ind for New Asset Dmx-652

THOMSON REUTERS

Soekarno-Hatta Set to Welcome Emirates' Giant A380

Dimerix Secures US Patent Regarding Kidney Injury Drug Candidate, Shares Jump 4%

MT Newswires Live

Dimerix Ltd-us Patent Granted for Dimerix New Asset Dmx-652

THOMSON REUTERS

Dimerix Acquires Phase 2-ready Acute Kidney Injury Drug Candidate Dmx-652 from Mission Therapeutics

Dimerix - Buys Dmx-652 for All Indications from Mission Therapeutics

THOMSON REUTERS

Dimerix - to Pay $5 Mln Upfront, up to $287 Mln in Milestones for Dmx-652

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg1.tigeractivity.com/stock/DXB.AU/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"DXB.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"DXB.AU\",,,,,undefined,":{"symbol":"DXB.AU","market":"AU","secType":"STK","nameCN":"DIMERIX LTD","latestPrice":0.23,"timestamp":1790748720000,"preClose":0.23,"halted":0,"volume":271613,"delay":0,"changeRate":0,"nameEN":"DIMERIX LTD","floatShares":467696880,"shares":600396776,"eps":-0.0497,"marketStatus":"Not Yet Opened","change":0,"latestTime":"09-30 16:12:00 AEST","open":0.235,"high":0.235,"low":0.225,"amount":62830,"amplitude":0.043478,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.0497,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1790812800000},"marketStatusCode":0,"adr":0,"exchange":"ASX","adjPreClose":0.23,"openAndCloseTimeList":[[1790726400000,1790748000000]],"volumeRatio":0.3242399288665511,"lotSize":1,"tradeCurrency":"AUD","auctionPricing":{"symbol":"DXB.AU","preClose":0.23,"auctionPrice":0.235,"auctionVolume":90,"auctionTime":1790807292830,"referenceTime":1790764203089,"auction":1,"marketStatus":"盘前竞价","timestamp":1790807292830}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"DXB.AU\",,,,,undefined,":{"symbol":"DXB.AU","floatShares":467696880,"roa":"-29.36%","roe":"-594.54%","lyrEps":-0.0497,"volumeRatio":0.3242399288665511,"shares":600396776,"dividePrice":0,"high":0.235,"amplitude":0.043478,"preClose":0.23,"low":0.225,"week52Low":0.157,"pbRate":"-9.36","psRate":"21.73","week52High":0.665,"institutionHeld":0,"latestPrice":0.23,"eps":-0.0497,"divideRate":0,"volume":271613,"delay":0,"ttmEps":-0.0497,"open":0.235,"prevYearClose":0.55,"prevWeekClose":0.225,"prevMonthClose":0.23,"prevQuarterClose":0.23,"fiveDayClose":0.235,"twentyDayClose":0.29,"sixtyDayClose":0.24,"dividendGrowthYears":0,"fiveYearAvgDividendRate":0},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/DXB.AU\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"DXB.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"DXB.AU\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2669736001","title":"Dimerix Receives AU$17 Million in Proceeds After Completing Initial Drawdown Under Non-Dilutive Funding Facility","url":"https://stock-news.laohu8.com/highlight/detail?id=2669736001","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669736001?lang=en_us&edition=fundamental","pubTime":"2026-09-23 08:17","pubTimestamp":1790122651,"startTime":"0","endTime":"0","summary":"Dimerix  confirmed that it completed an initial drawdown under its AU$34 million non-dilutive funding facility, receiving gross proceeds of AU$17 million, according to a Wednesday Australian bourse filing.The remaining AU$17 million is available for drawdown at the firm's election until March 31, 2027, subject to facility terms, the company said.It also confirmed that it was funded through to the delivery of the Action3 phase three trial of its DMX-200 treatment candidate in patients with focal segmental glomerulosclerosis, a rare kidney disease, and continued advancement of the phase two trial of DMX-652 in acute kidney injury.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["DXB.AU","BK7501","BK7508","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669115427","title":"Dimerix Ltd-Waiver of Listing Rule 10.1 Granted","url":"https://stock-news.laohu8.com/highlight/detail?id=2669115427","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669115427?lang=en_us&edition=fundamental","pubTime":"2026-09-22 13:46","pubTimestamp":1790055990,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260922:nTUE3SH9TS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","BK7501","DXB.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669115404","title":"Dimerix - Waiver Permits Security Grant to Skiptan Entities Without Shareholder Approval","url":"https://stock-news.laohu8.com/highlight/detail?id=2669115404","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669115404?lang=en_us&edition=fundamental","pubTime":"2026-09-22 13:46","pubTimestamp":1790055990,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260922:nTUE3SH9TS:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","DXB.AU","BK7501","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667632159","title":"Australia's Dimerix Rises on Patent Approval in Mexico","url":"https://stock-news.laohu8.com/highlight/detail?id=2667632159","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667632159?lang=en_us&edition=fundamental","pubTime":"2026-09-14 11:59","pubTimestamp":1789358350,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's Dimerix rises on patent approval in Mexico** Shares of Australia's DimerixDXB.AXrise as much as 10% to A$0.275, marking their biggest pct gain since August 20** Clinical-stage biopharmaceutical company says Mexico has granted a patent for DMX-652, a drug candidate for acute kidney injury** The patent expands protection for DMX-652 in Mexico, one of Latin America's largest pharmaceutical markets** Co says the approval strengthens the commercial potential of DMX-652, following a similar approval for the drug in U.S.** YTD down 53.6%, including the session's moves","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260914:nL4N45604Y:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DXB.AU","BK7501","BK7508","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667368026","title":"Dimerix Says Mexican Composition of Matter Patent Granted for Drug Candidate","url":"https://stock-news.laohu8.com/highlight/detail?id=2667368026","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667368026?lang=en_us&edition=fundamental","pubTime":"2026-09-14 08:06","pubTimestamp":1789344401,"startTime":"0","endTime":"0","summary":"Dimerix  said the Mexican Institute of Industrial Property  granted a key composition of matter patent covering its drug candidate, DMX-652, according to a Monday Australian bourse filing.The patent grant \"N-cyanopyrrolidines with activity as USP30 inhibitors\" was issued under patent number 438406 and provides composition of matter protection for DMX-652 until June 3, 2041.The company's planned phase 2 study of DMX-652 in cardiac surgery-associated acute kidney injury will investigate the candidate's potential to prevent kidney injury and preserve renal function.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["DXB.AU","BK7067","DMX","USRD","BK7501","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667633298","title":"Dimerix Ltd-Dimerix Dmx-652 Granted Mexican Composition of Matter Patent","url":"https://stock-news.laohu8.com/highlight/detail?id=2667633298","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667633298?lang=en_us&edition=fundamental","pubTime":"2026-09-14 06:39","pubTimestamp":1789339172,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260913:nTUE3BDS1R:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7501","DXB.AU","BK7067","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664800459","title":"Dimerix Secures AU$34 Million in Non-Dilutive Loan Facility Agreements; Shares Up 4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2664800459","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664800459?lang=en_us&edition=fundamental","pubTime":"2026-09-04 08:40","pubTimestamp":1788482421,"startTime":"0","endTime":"0","summary":"Dimerix  secured non-dilutive loan facility agreements with a syndicate of Australian and US-based lenders to access up to AU$34 million, according to a Friday Australian bourse filing.This included a previously announced initial facility agreement of AU$10 million with Skiptan, per the filing. The firm confirmed that it was funded through to completion of the Action3 phase 3 trial in DMX-200, as well as the planned phase 2 clinical trial in DMX-652.The facility carries an interest rate of 10% per year, compounding annually, the company said. The receipt of the initial 50% draw-down is anticipated by Sept. 18, and the remainder is expected to take place at the firm's discretion on or before March 31, 2027.The facility provides the flexibility for Dimerix to elect to take further commitments for up to a total of AU$50 million on or before March 31, 2027.The biopharmaceutical company's shares were up 4% in recent Friday trade.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7067","DXB.AU","BK7508","BK7501"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664802749","title":"Dimerix Ltd - Secures A$34 Mln Non-Dilutive Funding Facility","url":"https://stock-news.laohu8.com/highlight/detail?id=2664802749","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664802749?lang=en_us&edition=fundamental","pubTime":"2026-09-04 07:17","pubTimestamp":1788477460,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260903:nFWN44V175:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","DXB.AU","BK7501","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664864668","title":"Dimerix - Trading Halt Requested Pending Announcement on Non-Dilutive Funding Arrangements","url":"https://stock-news.laohu8.com/highlight/detail?id=2664864668","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664864668?lang=en_us&edition=fundamental","pubTime":"2026-09-02 06:43","pubTimestamp":1788302639,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260901:nFWN44T15S:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7501","BK7067","DXB.AU","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662721510","title":"Dimerix Posts Loss for Year Attributable of A$29.8 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2662721510","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662721510?lang=en_us&edition=fundamental","pubTime":"2026-08-27 09:49","pubTimestamp":1787795375,"startTime":"0","endTime":"0","summary":"Aug 27 (Reuters) - Dimerix Ltd::*LOSS FOR THE YEAR ATTRIBUTABLE A$29.8 MILLION*REVENUES FROM ORDINARY ACTIVITIES FOR THE YEAR A$7 MILLION*Further company coverage: DXB.AX* ((Reuters.Briefs@thomsonreut","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260827:nRSD9nJQBR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DXB.AU","BK7501","BK7508","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662282967","title":"Dimerix Ltd - Loss for the Year Attributable A$29.8 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2662282967","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662282967?lang=en_us&edition=fundamental","pubTime":"2026-08-27 06:58","pubTimestamp":1787785108,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260826:nFWN44N17L:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["DXB.AU","BK7508","BK7067","BK7501"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660340889","title":"Dimerix Receives Initial $10 Million Upfront Payment Under Everest Medicines License Deal; Shares Gain 4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2660340889","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660340889?lang=en_us&edition=fundamental","pubTime":"2026-08-20 11:53","pubTimestamp":1787197984,"startTime":"0","endTime":"0","summary":"Dimerix  received an initial $10 million upfront payment under a license agreement with Everest Medicines, according to a Thursday filing with the Australian bourse.Everest holds exclusive rights to commercialize DMX-200 for the treatment of kidney disease focal segmental glomerulosclerosis across Greater China, South Korea, and Southeast Asia.Dimerix said it is eligible to receive up to an additional $330 million in success-based development, regulatory, and commercial milestone payments, in addition to tiered royalties on net sales of the DMX-200 in the licensed regions.The company's shares gained 4% in recent Thursday trade.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["DXB.AU","BK7501","BK7508","BK7067","MDCO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660243106","title":"Dimerix Completes Transfer of Acute Kidney Injury Drug Candidate's US Investigational New Drug Application, Shares Up 6%","url":"https://stock-news.laohu8.com/highlight/detail?id=2660243106","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660243106?lang=en_us&edition=fundamental","pubTime":"2026-08-17 09:43","pubTimestamp":1786930994,"startTime":"0","endTime":"0","summary":"Dimerix  said it completed the transfer of the investigational new drug application in the US for its acute kidney injury drug candidate, DMX-652, from Mission Therapeutics, according to a Monday Australian bourse filing.Dimerix plans to advance DMX-652 into a phase 2 clinical trial for acute kidney injury associated with cardiac surgery during the second half, to investigate its potential to prevent kidney injury and preserve renal function.Its shares jumped 6% in recent trading on Monday.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["DXB.AU","BK7067","BK7501","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660875103","title":"Dimerix Ltd-Dimerix Assumes Sponsorship of US Ind for New Asset Dmx-652","url":"https://stock-news.laohu8.com/highlight/detail?id=2660875103","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660875103?lang=en_us&edition=fundamental","pubTime":"2026-08-17 06:38","pubTimestamp":1786919913,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260816:nTUE7JZ8SR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","DXB.AU","BK7501","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655355611","title":"Soekarno-Hatta Set to Welcome Emirates' Giant A380","url":"https://stock-news.laohu8.com/highlight/detail?id=2655355611","media":"Tempo","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655355611?lang=en_us&edition=fundamental","pubTime":"2026-07-31 12:54","pubTimestamp":1785473684,"startTime":"0","endTime":"0","summary":"TEMPO.CO, Jakarta - Soekarno-Hatta International Airport, operated under InJourney Airports , is set to welcome the inaugural landing of Emirates Airlines' Airbus A380-800, which will operate flight EK358 from Dubai  to Jakarta .Soekarno-Hatta International Airport General Manager Heru Karyadi stated that the world's largest passenger airliner is scheduled to touch down in Jakarta on August 8, 2026, at 10:25 p.m. Jakarta time  before making its return journey to Dubai as flight EK359 on August 9, 2026, at 12:45 a.m. WIB.\"The arrival of the Airbus A380-800 is a major milestone in expanding Indonesia's international air connectivity,\" Heru said on Friday, July 31, 2026.","market":"other","thumbnail":"https://statik.tempo.co/data/2023/06/02/id_1208747/1208747_720.jpg","type":0,"news_type":0,"thumbnails":["https://statik.tempo.co/data/2023/06/02/id_1208747/1208747_720.jpg"],"rights":{"source":"tempo_highlight","url":"https://en.tempo.co/read/2116268/soekarno-hatta-set-to-welcome-emirates-giant-a380","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://en.tempo.co/read/2116268/soekarno-hatta-set-to-welcome-emirates-giant-a380","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tempo_highlight","symbols":["BK7501","PCR","DXB.AU","DXB","BK7067","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653797401","title":"Dimerix Secures US Patent Regarding Kidney Injury Drug Candidate, Shares Jump 4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2653797401","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653797401?lang=en_us&edition=fundamental","pubTime":"2026-07-23 09:27","pubTimestamp":1784770064,"startTime":"0","endTime":"0","summary":"Dimerix  said the United States Patent and Trademark Office granted a patent providing composition-of-matter-type claims covering the firm's drug candidate, DMX-652, until April 11, 2043, according to a Thursday Australian bourse filing.The candidate is a selective inhibitor of USP30, a mitochondrial enzyme, designed to prevent kidney injury and promote mitophagy where damage has occurred. A divisional application has also been filed to pursue additional claims covering DMX-652, the filing added.Its shares rose 4% in recent trading on Thursday.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7508","BK7067","DXB.AU","BK7501"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653791917","title":"Dimerix Ltd-us Patent Granted for Dimerix New Asset Dmx-652","url":"https://stock-news.laohu8.com/highlight/detail?id=2653791917","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653791917?lang=en_us&edition=fundamental","pubTime":"2026-07-23 06:46","pubTimestamp":1784760416,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260722:nTUE4PKSZB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","DXB.AU","BK7501","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652407438","title":"Dimerix Acquires Phase 2-ready Acute Kidney Injury Drug Candidate Dmx-652 from Mission Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2652407438","media":"Reuters","labels":["corporation","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652407438?lang=en_us&edition=fundamental","pubTime":"2026-07-17 19:02","pubTimestamp":1784286128,"startTime":"0","endTime":"0","summary":"Dimerix acquires Phase 2-ready acute kidney injury drug candidate DMX-652 from Mission TherapeuticsDimerix acquired DMX-652 from Mission Therapeutics for all indications, adding a Phase 2-ready acute ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260717:nNDLbGlB3s:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Dimerix Acquires Phase 2-ready Acute Kidney Injury Drug Candidate Dmx-652 from Mission Therapeutics","news_tag":"corporation,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7501","BK7067","DXB.AU","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652740715","title":"Dimerix - Buys Dmx-652 for All Indications from Mission Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2652740715","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652740715?lang=en_us&edition=fundamental","pubTime":"2026-07-17 19:00","pubTimestamp":1784286002,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260717:nTUA58K1YY:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","DXB.AU","BK7501","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652152407","title":"Dimerix - to Pay $5 Mln Upfront, up to $287 Mln in Milestones for Dmx-652","url":"https://stock-news.laohu8.com/highlight/detail?id=2652152407","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652152407?lang=en_us&edition=fundamental","pubTime":"2026-07-17 19:00","pubTimestamp":1784286002,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260717:nTUA58K1YY:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","DXB.AU","BK7508","BK7501"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":1,"totalSize":45,"code":"91000000","status":"200"}]}}